Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.5.2093

Once-weekly Subcutaneous Administration of Bortezomib in Patients with Multiple Myeloma  

Wang, Liang (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine)
Wang, Ke-Feng (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine)
Chang, Bo-Yang (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine)
Chen, Xiao-Qin (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine)
Xia, Zhong-Jun (Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.5, 2015 , pp. 2093-2098 More about this Journal
Abstract
In patients with multiple myeloma (MM), once-weekly intravenous injection or twice-weekly subcutaneous injection (SC) of bortezomib has been proven to offer non-inferior efficacy to standard twice-weekly intravenous administration, with an improved safety profile. However, whether once-weekly SC bortezomib can further reduce the incidence rate of peripheral neuropathy (PN) and not compromise the efficacy remains to be investigated. 25 patients of MM treated with once-weekly SC bortezomib were reviewed in this study. The median treatment cycles were 4 (range, 2-9 cycles). Complete response (CR) rate was 52%, ${\geq}$very good partial response (VGPR) rate was 72%, and ${\geq}$partial response (PR) rate was 84%. 1-year and 2-year PFS rate was 63.0% and 34.3%, respectively, and 2-year OS rate was 100%. Any grade of PN was reported in 9 patients (36.0%), with 7 patients (28.0%) had grade 1 PN, and 2 patients (8.0%) had grade 2 PN. No patients reported grade 3/4 PN in this cohort. In conclusion, once-weekly subcutaneous administration of bortezomib offers excellent efficacy with a further improved safety profile, especially with regard to PN. It needs to be validated in future prospective randomized trials.
Keywords
Bortezomib; subcutaneous; multiple myeloma; peripheral neuropathy; efficacy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Avet-Loiseau H, Leleu X, Roussel M, et al (2010). Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol, 28, 4630-4.   DOI
2 Badros A, Goloubeva O, Dalal J S, et al (2007). Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer, 110, 1042-9.   DOI
3 Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF (2013). Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood, 121, 884-92.   DOI
4 Bringhen S, Larocca A, Rossi D, et al (2010). Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 116, 4745-53.   DOI
5 Chanan-Khan A A, and Giralt S (2010). Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol, 28, 2612-24.   DOI   ScienceOn
6 Durie B G, Harousseau J L, Miguel J S, et al (2006). International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-73.   DOI
7 Engelhardt M, Kleber M, Udi J, et al (2010). Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma, 51, 1424-43.   DOI
8 Harousseau J L, Attal M, and Avet-Loiseau H (2009). The role of complete response in multiple myeloma. Blood, 114, 3139-46.   DOI
9 Kapoor P, Kumar S K, Dispenzieri A, et al (2013). Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol, 31, 4529-35.   DOI
10 Knopf KB, Duh MS, Lafeuille MH, et al (2014). Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk, 14, 380-8.   DOI
11 Koh Y, Lee S Y, Kim I, et al (2014). Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer Chemother Pharmacol, 74, 653-7.   DOI
12 Moreau P, Pylypenko H, Grosicki S, et al (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol, 12, 431-40.   DOI
13 Kumar SK, Rajkumar SV, Dispenzieri A, et al (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-20.   DOI
14 Lu J, Lu J, Chen W, et al (2014). Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J, 4, 239.   DOI
15 Mateos M V (2010). Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev, 36, 24-32.   DOI   ScienceOn
16 Morgan GJ (2013). Transplants for the elderly in myeloma. Blood, 122, 1332-4.   DOI
17 Nooka AK, Kaufman JL, Behera M, et al (2013). Bortezomibcontaining induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer, 119, 4119-28.   DOI
18 Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson K C (2009). Multiple myeloma. Lancet, 374, 324-39.   DOI
19 Reeder CB, Reece DE, Kukreti V, et al (2010). Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 115, 3416-7.   DOI
20 Richardson PG, Briemberg H, Jagannath S, et al (2006). Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol, 24, 3113-20.   DOI   ScienceOn
21 Sonneveld P, Schmidt-Wolf I G, van der Holt B, et al (2012). Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol, 30, 2946-55.   DOI
22 Richardson PG, Delforge M, Beksac M, et al (2012). Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 26, 595-608.   DOI
23 Roschewski M, Korde N, Wu SP and Landgren O (2013). Pursuing the curative blueprint for early myeloma. Blood, 122, 486-90.   DOI
24 Sonneveld P, Goldschmidt H, Rosinol L, et al (2013). Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol, 31, 3279-87.   DOI
25 Voorhees P M, Laubach J, Anderson K C and Richardson P G (2013). Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood, 121, 858.   DOI
26 Wang A, Duan Q, Liu X, et al (2012). (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/ thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol, 91, 1779-84.   DOI